You are here

Global Market for Biosimilars Expected To Explode

It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.

The U.S. may be a little wary when it comes to approving biosimilars, but the rest of the world seems to have jumped in with both feet. The global market for biosimilars will grow from $5.95 billion this year to $23.63 billion by 2023, according to a report by ResearchAndMarkets. The reason is simple enough, they’re less costly than the reference biologic, but concerns remain about regulatory guidelines concerning how biosimilars should be manufactured.

The report states that the non-glycosylated proteins portion of the market accounted for the biggest share in 2017, but recombinant glycosylated proteins are expected to hold the largest share in the near future.

Sources: Business Wire; MedCity News

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring